Epigenomics Reports 81 Percent Drop in Q2 Revenues; Takeover Bid Fails

Aug 09, 2017

|

NEW YORK (GenomeWeb) – Epigenomics reported today that its second quarter revenues dropped 81 percent due to lower orders of its Epi proColon colorectal cancer test and a continued lack of reimbursement coverage for its products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Epigenomics Reports 81 Percent Drop in Q2 Revenues; Takeover Bid Fails

To read the full story....

Breaking News

Somalogic Closes $121M Series A Funding

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Featured White Papers

What's Popular?

European Consortium Seeks to Develop Liquid Biopsy Test for Prostate, Testicular Cancer

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

BTIG Downgrades Fulgent Genetics from Buy to Neutral

FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

Sponsorships